Abstract:Steroid‐resistant asthma, including airway remodelling and increases in group 2 innate lymphoid cells (ILC2s), was suppressed in mice by the pan‐Janus kinase (JAK) inhibitor, delgocitinib, or the Bcl‐xL inhibitor, navitoclax. A stimulation of ILC2s with the combined treatment of IL‐33, thymic stromal lymphopoietin, and IL‐7 induced their proliferation and concomitantly up‐regulated the expression of Bcl‐xL, an anti‐apoptotic factor. These changes were resistant to steroids, but were markedly suppressed by delgocitinib or navitoclax. Therefore, the inhibition of JAKs or Bcl‐xL has potential as pharmacotherapy for steroid‐resistant asthma, particularly that mediated by ILC2s. The mechanisms underlying the development of steroid resistance in asthma remain unclear. To establish whether as well as the mechanisms by which the activation of Janus kinases (JAKs) is involved in the development of steroid resistance in asthma, murine steroid‐resistant models of the proliferation of group 2 innate lymphoid cells (ILC2s) in vitro and asthmatic airway inflammation in vivo were analysed. ILC2s in the lungs of BALB/c mice were sorted and then incubated with IL‐33, thymic stromal lymphopoietin (TSLP), and/or IL‐7 with or without dexamethasone (10 nM), the pan‐JAK inhibitor, delgocitinib (1–10 000 nM), and/or the Bcl‐xL inhibitor, navitoclax (1–100 nM), followed by the detection of viable and apoptotic cells. The anti‐apoptotic factor, Bcl‐xL was detected in ILC2s by flow cytometry. As a steroid‐resistant asthma model, ovalbumin (OVA)‐sensitized BALB/c mice were intratracheally challenged with OVA at a high dose of 500 μg four times. Dexamethasone (1 mg/kg, i.p.), delgocitinib (3–30 mg/kg, p.o.), or navitoclax (30 mg/kg, p.o.) was administered during the challenges. Cellular infiltration into the lungs was analysed by flow cytometry. Airway remodelling was histologically evaluated. The following results were obtained. (1) Cell proliferation concomitant with a decrease in apoptotic cells was induced when ILC2s were cultured with TSLP and/or IL‐7, and was potently inhibited by dexamethasone. In contrast, when the culture with TSLP and IL‐7 was performed in the presence of IL‐33, the proliferative response exhibited steroid resistance. Steroid‐resistant ILC2 proliferation was suppressed by delgocitinib in a concentration‐dependent manner. (2) The culture with IL‐33, TSLP, and IL‐7 induced the overexpression of Bcl‐xL, which was clearly inhibited by delgocitinib, but not by dexamethasone. When ILC2s were treated with navitoclax, insensitivity to dexamethasone was significantly cancelled. (3) The development of airway remodelling and the infiltration of ILC2s into the lungs in the asthma model were not suppressed by dexamethasone, but were dose‐dependently inhibited by delgocitinib. Combination treatment with dexamethasone and either delgocitinib or navitoclax synergistically suppressed these responses. Therefore, JAKs appear to play significant roles in the induction of steroid resistance by up‐regulating Bcl‐xL in ILC2s. The inhibition of JAKs and Bcl‐xL has potential as pharmacotherapy for steroid‐resistant asthma, particularly that mediated by ILC2s.

Induction of Granulocyte Apoptosis by Bcl-2 Inhibitors Reduces Steroid-Insensitive Airway Inflammation

Bcl-2 Inhibitors Reduce Steroid-Insensitive Airway Inflammation.

Bcl-2 Antagonist ABT-737 Attenuates Corticosteroid-Insensitive Neutrophilic Airway Inflammation

Induction of Neutrophil Apoptosis by a Bcl-2 Inhibitor Reduces Particulate Matter-Induced Lung Inflammation

Nanoformulated ABT-199 to Effectively Target Bcl-2 at Mitochondrial Membrane Alleviates Airway Inflammation by Inducing Apoptosis

Bruton's tyrosine kinase inhibition suppresses neutrophilic inflammation and restores histone deacetylase 2 expression in myeloid and structural cells in a mixed granulocytic mouse model of asthma

Depletion of Major Pathogenic Cells in Asthma by Targeting CRTh2

Low Doses Of Exogenous Interferon-Gamma Attenuated Airway Inflammation Through Enhancing Fas/Fasl-Induced Cd4(+) T Cell Apoptosis In A Mouse Asthma Model

Involvement of Janus kinase‐dependent Bcl‐xL overexpression in steroid resistance of group 2 innate lymphoid cells in asthma

Chemical Chaperones Reverses Autophagic Dysfunction Resulting From Bronchial Asthma in the Lung Tissues of OVA-OVA Mice via Modulating NF-κB Activation

Combined Treatment with SB203580 and Dexamethasone Suppresses Non-Typeable Haemophilus Influenzae-Induced Th17 Inflammation Response in Murine Allergic Asthma.

Budesonide Suppresses Pulmonary Antibacterial Host Defense by Down-Regulating Cathelicidin-Related Antimicrobial Peptide in Allergic Inflammation Mice and in Lung Epithelial Cells

Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide

The role of JAK/STAT signaling in neutrophilic airway inflammation

Pathogenesis of steroid-resistant airway hyperresponsiveness: interaction between IFN-gamma and TLR4/MyD88 pathways

Decrease in Airway Mucous Gene Expression Caused by Treatment with Anti-Tumor Necrosis Factor Alpha in A Murine Model of Allergic Asthma

Natural killer cell–mediated inflammation resolution is disabled in severe asthma

Association of NR3C1 Bcl1 gene polymorphism with impaired programmed cell death of lymphocytes in patients with atopic bronchial asthma

Effects of Glucocorticoid and Cysteinyl Leukotriene 1 Receptor Antagonist on CD(34+) Hematopoietic Cells in Bone Marrow of Asthmatic Mice.

Intervention with ICOSL Antibodies Alleviates Inflammatory Infiltrations in Mice with Neutrophilic Asthma.

Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity